Verrica COO granted 171,340 stock options

Verrica Pharmaceuticals Inc. reported that Chief Operating Officer David Zawitz received a grant of employee stock options for 171,340 shares of common stock.

Rhea-AI Filing Summary

Verrica Pharmaceuticals Inc. reported that Chief Operating Officer David Zawitz received a grant of employee stock options for 171,340 shares of common stock. The options have an exercise price of $8.21 per share and expire on December 23, 2035.

The grant was approved by a board committee on December 23, 2025, subject to shareholder approval of an amendment to the 2018 Equity Incentive Plan, which shareholders granted on June 5, 2026. Half of the options vest only if the share price reaches $15.00, and the other half vest if the share price reaches $25.00, in each case subject to Zawitz’s continuous service.

Insider Trade Summary

Grant/Award: 171,340 shares

Grant/Award 1 txn

Insider Zawitz David

Role Chief Operating Officer

Type	Security	Shares	Price	Value
Grant/Award	Employee Stock Option (right to buy)	171,340	$0.00	$0.00

Holdings After Transaction: Employee Stock Option (right to buy) — 171,340 contracts (Direct)

Footnotes (2)

1. F1. The option grant was approved by a committee of the Issuer's board of directors on December 23, 2025, subject to shareholder approval of an amendment to the Issuer's 2018 Equity Incentive Plan under which the option was granted. The Issuer's shareholders approved the amendment on June 5, 2026.
2. F2. 50% of the total shares subject to the option shall vest on the date that the closing sales price per share of the Issuer's Common Stock as reported on The Nasdaq Capital Market equals at least $15.00, and 50% of the total shares subject to the option shall vest on the date that the closing sales price per share of the Issuer's Common Stock as reported on The Nasdaq Capital Market equals at least $25.00, subject to the Reporting Person's continuous service through each such vesting date.

Key Figures

Option grant size: 171,340 shares Exercise price: $8.21 per share Expiration date: December 23, 2035 +2 more

5 metrics

Option grant size 171,340 shares Employee stock option grant to COO David Zawitz

Exercise price $8.21 per share Exercise price of granted stock options

Expiration date December 23, 2035 Option expiration for the grant

Vesting hurdle 1 $15.00 share price 50% of options vest when closing price reaches at least $15.00

Vesting hurdle 2 $25.00 share price 50% of options vest when closing price reaches at least $25.00

Key Terms

Employee Stock Option (right to buy), 2018 Equity Incentive Plan, vesting, closing sales price

4 terms

Employee Stock Option (right to buy) financial

"security_title: Employee Stock Option (right to buy)"

2018 Equity Incentive Plan financial

"shareholder approval of an amendment to the Issuer's 2018 Equity Incentive Plan"

vesting financial

"50% of the total shares subject to the option shall vest on the date"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

closing sales price financial

"on the date that the closing sales price per share of the Issuer's Common Stock"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Verrica (VRCA) report for David Zawitz?

Verrica reported a grant of employee stock options to COO David Zawitz covering 171,340 shares of common stock. This is a compensation-related award, not an open-market stock purchase or sale.

What are the key terms of David Zawitz’s Verrica (VRCA) stock options?

The options cover 171,340 shares with an exercise price of $8.21 per share and an expiration date of December 23, 2035. These terms define the price and time window for exercising the options.

How do the vesting conditions work for the Verrica (VRCA) options granted to Zawitz?

Fifty percent of the options vest when Verrica’s closing share price reaches at least $15.00, and the remaining 50% vest when it reaches at least $25.00, assuming Zawitz remains in continuous service until each vesting date.

When was the Verrica (VRCA) option grant to David Zawitz approved?

A board committee approved the option grant on December 23, 2025, subject to shareholder approval of an amendment to the 2018 Equity Incentive Plan. Shareholders approved that amendment on June 5, 2026.

Is the Verrica (VRCA) option grant to Zawitz an open-market transaction?

No. The filing shows a grant/award acquisition of employee stock options, coded as an “A” transaction. This represents compensation, not buying or selling Verrica shares on the open market.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/09/2026 - 04:15 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Zawitz David

(Last) (First) (Middle)

C/O VERRICA PHARMACEUTICALS INC.

44 W. GAY ST., SUITE 400

(Street)

WEST CHESTER PENNSYLVANIA 19380

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Verrica Pharmaceuticals Inc. [ VRCA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Operating Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/05/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (right to buy)	$8.21	06/05/2026(1)		A		171,340		(2)	12/23/2035	Common Stock	171,340	$0	171,340	D

Explanation of Responses:

1. The option grant was approved by a committee of the Issuer's board of directors on December 23, 2025, subject to shareholder approval of an amendment to the Issuer's 2018 Equity Incentive Plan under which the option was granted. The Issuer's shareholders approved the amendment on June 5, 2026.

2. 50% of the total shares subject to the option shall vest on the date that the closing sales price per share of the Issuer's Common Stock as reported on The Nasdaq Capital Market equals at least $15.00, and 50% of the total shares subject to the option shall vest on the date that the closing sales price per share of the Issuer's Common Stock as reported on The Nasdaq Capital Market equals at least $25.00, subject to the Reporting Person's continuous service through each such vesting date.

	/s/ Jayson Rieger, Attorney-in-Fact	06/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)